Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2

Brian Titus, Henry F. Frierson, Mark Conaway, Keith Ching, Theresa Guise, John Chirgwin, Garret Hampton, Dan Theodorescu

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Half of patients treated for locally advanced bladder cancer relapse with often fatal metastatic disease to the lung. We have recently shown that reduced expression of the GDP dissociation inhibitor, RhoGDI2, is associated with decreased survival of patients with advanced bladder cancer. However, the effectors by which RhoGDI2 affects metastasis are unknown. Here we use DNA microarrays to identify genes suppressed by RhoGDI2 reconstitution in lung metastatic bladder cancer cell lines. We identify such RNAs and focus only on those that also increase with tumor stage in human bladder cancer samples to discover only clinically relevant targets of RhoGDI2. Levels of endothelin-1 (ET-1), a potent vasoconstrictor, were affected by both RhoGDI2 reconstitution and tumor stage. To test the hypothesis that the endothelin axis is important in lung metastasis, lung metastatic bladder carcinoma cells were injected in mice treated with the endothelin receptor-specific antagonist, atrasentan, thereby blocking engagement of the up-regulated ET-1 ligand with its cognate receptor. Endothelin antagonism resulted in a dramatic reduction of lung metastases, similar to the effect of reexpressing RhoGDI2 in these metastatic cells. Taken together, these experiments show a novel approach of identifying therapeutic targets downstream of metastasis suppressor genes. The data also suggest that blockade of the ET-1 axis may prevent lung metastasis, a new therapeutic concept that warrants clinical evaluation.

Original languageEnglish (US)
Pages (from-to)7320-7327
Number of pages8
JournalCancer Research
Volume65
Issue number16
DOIs
StatePublished - Aug 15 2005
Externally publishedYes

Fingerprint

Endothelins
Tumor Suppressor Genes
Urinary Bladder Neoplasms
Endothelin-1
Lung
Neoplasm Metastasis
Guanine Nucleotide Dissociation Inhibitors
Vasoconstrictor Agents
Oligonucleotide Array Sequence Analysis
Lung Diseases
Neoplasms
Urinary Bladder
RNA
Ligands
Carcinoma
Recurrence
Cell Line
Survival
Therapeutics
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. / Titus, Brian; Frierson, Henry F.; Conaway, Mark; Ching, Keith; Guise, Theresa; Chirgwin, John; Hampton, Garret; Theodorescu, Dan.

In: Cancer Research, Vol. 65, No. 16, 15.08.2005, p. 7320-7327.

Research output: Contribution to journalArticle

Titus, B, Frierson, HF, Conaway, M, Ching, K, Guise, T, Chirgwin, J, Hampton, G & Theodorescu, D 2005, 'Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2', Cancer Research, vol. 65, no. 16, pp. 7320-7327. https://doi.org/10.1158/0008-5472.CAN-05-1403
Titus, Brian ; Frierson, Henry F. ; Conaway, Mark ; Ching, Keith ; Guise, Theresa ; Chirgwin, John ; Hampton, Garret ; Theodorescu, Dan. / Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. In: Cancer Research. 2005 ; Vol. 65, No. 16. pp. 7320-7327.
@article{ff204d9fb874450794caad7f24e1b6df,
title = "Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2",
abstract = "Half of patients treated for locally advanced bladder cancer relapse with often fatal metastatic disease to the lung. We have recently shown that reduced expression of the GDP dissociation inhibitor, RhoGDI2, is associated with decreased survival of patients with advanced bladder cancer. However, the effectors by which RhoGDI2 affects metastasis are unknown. Here we use DNA microarrays to identify genes suppressed by RhoGDI2 reconstitution in lung metastatic bladder cancer cell lines. We identify such RNAs and focus only on those that also increase with tumor stage in human bladder cancer samples to discover only clinically relevant targets of RhoGDI2. Levels of endothelin-1 (ET-1), a potent vasoconstrictor, were affected by both RhoGDI2 reconstitution and tumor stage. To test the hypothesis that the endothelin axis is important in lung metastasis, lung metastatic bladder carcinoma cells were injected in mice treated with the endothelin receptor-specific antagonist, atrasentan, thereby blocking engagement of the up-regulated ET-1 ligand with its cognate receptor. Endothelin antagonism resulted in a dramatic reduction of lung metastases, similar to the effect of reexpressing RhoGDI2 in these metastatic cells. Taken together, these experiments show a novel approach of identifying therapeutic targets downstream of metastasis suppressor genes. The data also suggest that blockade of the ET-1 axis may prevent lung metastasis, a new therapeutic concept that warrants clinical evaluation.",
author = "Brian Titus and Frierson, {Henry F.} and Mark Conaway and Keith Ching and Theresa Guise and John Chirgwin and Garret Hampton and Dan Theodorescu",
year = "2005",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-05-1403",
language = "English (US)",
volume = "65",
pages = "7320--7327",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2

AU - Titus, Brian

AU - Frierson, Henry F.

AU - Conaway, Mark

AU - Ching, Keith

AU - Guise, Theresa

AU - Chirgwin, John

AU - Hampton, Garret

AU - Theodorescu, Dan

PY - 2005/8/15

Y1 - 2005/8/15

N2 - Half of patients treated for locally advanced bladder cancer relapse with often fatal metastatic disease to the lung. We have recently shown that reduced expression of the GDP dissociation inhibitor, RhoGDI2, is associated with decreased survival of patients with advanced bladder cancer. However, the effectors by which RhoGDI2 affects metastasis are unknown. Here we use DNA microarrays to identify genes suppressed by RhoGDI2 reconstitution in lung metastatic bladder cancer cell lines. We identify such RNAs and focus only on those that also increase with tumor stage in human bladder cancer samples to discover only clinically relevant targets of RhoGDI2. Levels of endothelin-1 (ET-1), a potent vasoconstrictor, were affected by both RhoGDI2 reconstitution and tumor stage. To test the hypothesis that the endothelin axis is important in lung metastasis, lung metastatic bladder carcinoma cells were injected in mice treated with the endothelin receptor-specific antagonist, atrasentan, thereby blocking engagement of the up-regulated ET-1 ligand with its cognate receptor. Endothelin antagonism resulted in a dramatic reduction of lung metastases, similar to the effect of reexpressing RhoGDI2 in these metastatic cells. Taken together, these experiments show a novel approach of identifying therapeutic targets downstream of metastasis suppressor genes. The data also suggest that blockade of the ET-1 axis may prevent lung metastasis, a new therapeutic concept that warrants clinical evaluation.

AB - Half of patients treated for locally advanced bladder cancer relapse with often fatal metastatic disease to the lung. We have recently shown that reduced expression of the GDP dissociation inhibitor, RhoGDI2, is associated with decreased survival of patients with advanced bladder cancer. However, the effectors by which RhoGDI2 affects metastasis are unknown. Here we use DNA microarrays to identify genes suppressed by RhoGDI2 reconstitution in lung metastatic bladder cancer cell lines. We identify such RNAs and focus only on those that also increase with tumor stage in human bladder cancer samples to discover only clinically relevant targets of RhoGDI2. Levels of endothelin-1 (ET-1), a potent vasoconstrictor, were affected by both RhoGDI2 reconstitution and tumor stage. To test the hypothesis that the endothelin axis is important in lung metastasis, lung metastatic bladder carcinoma cells were injected in mice treated with the endothelin receptor-specific antagonist, atrasentan, thereby blocking engagement of the up-regulated ET-1 ligand with its cognate receptor. Endothelin antagonism resulted in a dramatic reduction of lung metastases, similar to the effect of reexpressing RhoGDI2 in these metastatic cells. Taken together, these experiments show a novel approach of identifying therapeutic targets downstream of metastasis suppressor genes. The data also suggest that blockade of the ET-1 axis may prevent lung metastasis, a new therapeutic concept that warrants clinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=23844468385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844468385&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-1403

DO - 10.1158/0008-5472.CAN-05-1403

M3 - Article

C2 - 16103083

AN - SCOPUS:23844468385

VL - 65

SP - 7320

EP - 7327

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 16

ER -